Cargando…
Immunotherapy of Malignant Disease Using Chimeric Antigen Receptor Engrafted T Cells
Chimeric antigen receptor- (CAR-) based immunotherapy has been under development for almost 25 years, over which period it has progressed from a new but cumbersome technology to an emerging therapeutic modality for malignant disease. The approach involves the genetic engineering of fusion receptors...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Scholarly Research Network
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523553/ https://www.ncbi.nlm.nih.gov/pubmed/23304553 http://dx.doi.org/10.5402/2012/278093 |